Table 1.

Phenotypic characteristics of case subjects with priapism and control subjects in a population of patients with SCD, presented as frequency (% of nonmissing)




Case subjects, no. (%); n = 273

Control subjects, no. (%); n = 979

Adjusted OR (95% CI)

P
SS   197 (72)   525 (54)   Reference   NA  
SSα   45 (16)   189 (19)   0.6 (0.4–0.9)   .019  
SC   31 (11)   265 (27)   0.2 (0.1–0.4)   < .001  
Haplotype     
   BEN/BEN   38 (41)   127 (47)   Reference   NA  
   BEN/CAR   23 (25)   74 (27)   1.7 (0.9–3.2)   .099  
   BEN/SEN   11 (12)   30 (11)   1.2 (0.6–2.7)   .610  
   Other   21 (23)   41 (15)   1.0 (0.6–1.9)   .900  
Stroke*  24 (9)   52 (5)   1.7 (1.0–2.8)   .053  
AVN  121 (44)   341 (35)   1.5 (1.1–1.9)   .006  
ACS  218 (80)   619 (63)   2.2 (1.6–3.0)   < .001  
Pain  253 (93)   815 (83)   2.3 (1.4–3.8)   < .001  
Proteinuria   28 (14)   54 (7)   1.5 (0.9–2.6)   .106  
Supplemental folate   198 (84)   663 (79)   1.5 (1.0–2.2)   .047  
Supplemental iron   5.88 (4)   48 (6)   0.7 (0.3–1.3)   .276  
Blood pressure medication   11 (5)   32 (4)   1.0 (0.5–2.1)   .933  
Heart medication   13 (6)   37 (5)   0.9 (0.5–1.9)   .873  
Ever smoked   116 (95)   228 (90)   1.8 (0.7–1.6)   .225  
Uses alcohol   90 (47)   230 (35)   1.4 (1.0–2.0)   .067  
Chronic transfusions
 
19 (9)
 
39 (6)
 
1.6 (0.9–2.9)
 
.104
 



Case subjects, no. (%); n = 273

Control subjects, no. (%); n = 979

Adjusted OR (95% CI)

P
SS   197 (72)   525 (54)   Reference   NA  
SSα   45 (16)   189 (19)   0.6 (0.4–0.9)   .019  
SC   31 (11)   265 (27)   0.2 (0.1–0.4)   < .001  
Haplotype     
   BEN/BEN   38 (41)   127 (47)   Reference   NA  
   BEN/CAR   23 (25)   74 (27)   1.7 (0.9–3.2)   .099  
   BEN/SEN   11 (12)   30 (11)   1.2 (0.6–2.7)   .610  
   Other   21 (23)   41 (15)   1.0 (0.6–1.9)   .900  
Stroke*  24 (9)   52 (5)   1.7 (1.0–2.8)   .053  
AVN  121 (44)   341 (35)   1.5 (1.1–1.9)   .006  
ACS  218 (80)   619 (63)   2.2 (1.6–3.0)   < .001  
Pain  253 (93)   815 (83)   2.3 (1.4–3.8)   < .001  
Proteinuria   28 (14)   54 (7)   1.5 (0.9–2.6)   .106  
Supplemental folate   198 (84)   663 (79)   1.5 (1.0–2.2)   .047  
Supplemental iron   5.88 (4)   48 (6)   0.7 (0.3–1.3)   .276  
Blood pressure medication   11 (5)   32 (4)   1.0 (0.5–2.1)   .933  
Heart medication   13 (6)   37 (5)   0.9 (0.5–1.9)   .873  
Ever smoked   116 (95)   228 (90)   1.8 (0.7–1.6)   .225  
Uses alcohol   90 (47)   230 (35)   1.4 (1.0–2.0)   .067  
Chronic transfusions
 
19 (9)
 
39 (6)
 
1.6 (0.9–2.9)
 
.104
 

SS indicates sickle cell anemia; NA, not applicable; SSα, sickle cell anemia-α thalassemia; SC, HbSC disease; BEN, Benin; CAR, Central African Republic; SEN, Senegal haplotypes.

*

Only about 30% of case and control subjects were successfully typed for β-globin gene haplotype; therefore, data are presented as number (% of nonmissing)

The CSSCD used the following definitions for these clinical events. AVN (avascular necrosis of humeral or femoral head) is defined as early radiographic findings of subephiphyseal lucency and widening of the joint space or late radiographic changes of flattening of the epiphysis and sclerosis with fragmentation. ACS (acute chest syndrome) is defined as a new pulmonary infiltrate that is demonstrable on a chest x-ray or by an isotope scan of the lungs, or evidence of pleuritic chest pain, with or without dyspnea, in the absence of a pulmonary infiltrate on the chest x-ray. If pleuritic pain is limited to the chest and chest films are negative, then a perfusion lung scan is required. Acute painful episode is defined as pain in the extremities, back, abdomen, chest, or head, for which no other explanation can be found and which is not classified as one of the other special events. Pain shall have lasted for at least 2 hours. If patient is old enough, he/she must have stated that pain is of nature usually associated with a crisis. Stroke, we only included in our analysis patients with a confirmed history of, or an incident, completed, nonhemorrhagic stroke, documented by imaging studies

or Create an Account

Close Modal
Close Modal